Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort
Home World News FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma
Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort
